BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives
Open Access
Abstract
Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy have improved survival in PM patients, but overall survival remains poor. Molecular analysis of PM patients has shown that most alterations occur in tumor suppressor genes, with BAP1 being the most frequently affected. Patients with germline BAP1 mutations have been reported to have a better prognosis, but this is not observed in those with somatic mutations. Interest in developing drugs targeting patients with BAP1 loss has led to several phase II studies in recent years. Unfortunately, initial results have not been very promising. In this review, we conclude that, at this time, with the contradictory results from studies and the limited number of patients evaluated, BAP1, the most commonly altered gene in PM, is not yet suitable for use in clinical practice as a prognostic or predictive factor. Future studies are needed to establish the prognostic or predictive value of BAP1.Keywords
This publication has 99 references indexed in Scilit:
- A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trialAnnals of Oncology, 2025
- Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural MesotheliomaJAMA Oncology, 2024
- First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743Annals of Oncology, 2022
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Annals of Oncology, 2022
- Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactionsEBioMedicine, 2019
- Loss of BRCA1‐associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusionsDiagnostic Cytopathology, 2017
- Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesotheliomaCancer Letters, 2017
- BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesotheliomaHuman Pathology, 2015
- Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high‐risk areaGenes, Chromosomes and Cancer, 2014
- Advances in the biology of malignant pleural mesotheliomaCancer Treatment Reviews, 2011